References
- Jabs D A, Enger C, Bartlett J G. Cytomegalovirus retinitis in acquired immunodeficiency syndrom. Arch Ophthalmol 1989; 107: 75–80
- Hoover D R, Saah A J, Bacellar H, Phair J, Detels R, Anderson R, Kaslow R A. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxi. New Engl J Med 1993; 329: 1922–1926
- Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Foscarnet-ganciclovir cytomegalovirus retinitis trial: 4. Visual outcomes. Ophthalmology 1994; 101: 1250–1261
- Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Arch Intern Med 1995; 155: 65–74
- Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326: 213–220
- The Oral Ganciclovir European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AID. AIDS 1995; 9: 471–477
- Dunn J P, MacCumber M W, Forman M S, Charache P, Apuzzo L, Jabs D A. Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovi. Am J Ophthalmol 1995; 119: 587–596
- Weinberg D V, Murphy R, Naughton K. Combined daily therapy with intravenous ganciclovir and foscarnet for patients with recurrent cytomegalovirus retiniti. Am J Ophthalmol 1994; 117: 776–782
- Cantrill H L, Henry K, Melroe N H, Knobloch W H, Ramsay R C, Balfour H H. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir. Long term result. Ophthalmology 1989; 96: 367–374
- Diaz-Llopis M, Espana E, Munoz G, Navea A, Chipont E, Cano J, et al. High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AID. Br J Ophthalmol 1994; 78: 120–124
- Martin D F, Parks D J, Mellow S D, Ferris F L, Walton R C, Remaley N A, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical tria. Arch Ophthalmol 1994; 112: 1531–1539
- Lalezari J P, Drew W L, Glutzer E, James C, Miner D, Flahery J, et al. (S)-1-[3-hydroxy-2-(phosphonyl-methoxy)propyl] cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogu. J Infect Dis 1995; 171: 788–796
- Kirsch L S, Arevalo J F, Chavez de la Paz E, Munguia D, de Clercq E, Freeman W R. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrom. Ophthalmology 1995; 102: 533–543